

THERAPEUTIC AREA	PRODUCT	INDICATION	API MICRONIZED	CEP/DMF
Antiallergics	Loratadine^P	Allergy	√	JP DMF
Antiasthmatics, COPD and respiratory diseases	Aclidinium bromide	COPD	√	EU-US DMF
	Arformoterol tartrate^P polymorph A and D	COPD	√	US-CN –KR DMF
	Formoterol fumarate	Asthma and COPD	√	CEP/US-JP-KR-CN-RU DMF
	Glycopyrronium bromide	COPD	√	CEP/ US-CN-KR-RU DMF
	Indacaterol maleate^P	Asthma and COPD	√	EU/US-KR-RU-CN DMF
	Montelukast sodium	Asthma, allergic & seasonal rhinitis		EU-JP DMF
	Revefenacin	COPD		EU & US-DMF
	Salmeterol xinafoate^P	Asthma and COPD	√	CEP/ US-CN-KR DMF
	Tiotropium bromide	COPD	√	CEP/US-CN-RU DMF
	Umeclidinium bromide	COPD	√	EU/US DMF
	Vilanterol trifenate	Asthma and COPD	√	EU/US DMF
	Antiemetics	Aprepitant	Emesis	√
Granisetron base^P		Emesis		US DMF
Granisetron hydrochloride^P		Emesis		CEP/ US-JP-KR DMF
Ondansetron base^P		Emesis	√	EU-US DMF
Ondansetron hydrochloride^P		Emesis	√	CEP/US DMF
Antihypertensive	Carvedilol^P	Hypertension, angina, heart failure		JP DMF
	Clevidipine^P	Hypertension		EU/US-CN DMF
	Enalapril maleate^P	Hypertension		CEP/KR DMF
	Imidapril	Hypertension		EU DMF
	Nitrendipine	Hypertension	√	CEP/DMF
Antimigrainics	Eletriptan HBr^P	Migraine	√	JP/RU DMF
	Rizatriptan benzoate^P	Migraine	√	EU-US DMF
	Zolmitriptan^P	Migraine	√	EU-US DMF
Antiparkinson	Tetrabenazine	Huntington's disease chorea and Tardive dyskinesia		EU-US DMF
Antipsychotics	Asenapine maleate^P	Schizophrenia and acute mania	√	JP DMF
	Olanzapine^P	Schizophrenia, psychosis		EU-US/KR DMF
	Quetiapine hemifumarate^P	Schizophrenia, psychosis		JP-KR DMF
	Risperidone^P	Schizophrenia, psychosis	√	CEP/US-KR/CN DMF
Antithrombotics	Prasugrel base^P	Prophylaxis & therapy of thrombosis		EU DMF
	Rivaroxaban	Thrombosis. Stroke		DMF
Spasmolytic	Otilonium bromide	Irritable bowel syndrome		EU DMF

CEP = Products with Certificate of Suitability / P = Patent applications/granted patents owned by INKE S.A.

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorization. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.